Conference Agenda
-
Sun 20th
-
Mon 21st
-
Tues 22nd
-
Wed 23rd
-
Thurs 24th
-
Delegates
-
Abstracts
| 1:00 pm to 5:00 pm |
Registration and Welcome Coffee
|
| |
Registration packets may be picked up from 1:00 - 5:00 pm, at the Conference.
Registration desk located on the Ballroom level. |
| 5.00 pm to 8.00 pm |
Innovations in Drug Candidate Development
|
| |
Chairman: Dr Trevor Laird, Scientific Update, UK
|
| 5.00 |
Dr Trevor Laird, Scientific Update, UK
An Overview of Drug Candidate Development: Industrial Case Studies |
| 5.45 |
Dr Carl Busacca, Boehringer-Ingelheim, USA
Development of a Manufacturing Route for the HCV Protease Inhibitor Faldaprevir |
| 6.30 |
Dr John Ragan, Pfizer, USA
Strategies for Chirality Control on Multi-Kilogram Scale: Development of an Enantioselctive Synthesis of Filibuvir |
| 7.15 |
Dr Diane Carrera, Genetech, USA
Early Process Research: Developing a Synthetic Strategy for PI3kd Inhibitors
|
| 8.00 pm - 10.00 pm |
Welcome Networking Reception
|
| 7.00 am - 8.00 am |
Good Morning Buffet Breakfast
|
| 8:00 am – 11:00 am |
Cancer Cell Metabolism and Opportunities for Therapeutic Intervention
|
| |
Chairman: Dr Tim Burkholder, Eli Lilly & Company, USA
|
| 8.00 |
Dr Sandaruwan Geeganage, Eli Lilly and Company, USA
Targeting Metabolic Reprogramming for Cancer |
| 8.30 |
Dr Richard Cerione, Cornell University, USA
New Strategies for Impacting Glutamine Metabolism in Cancer Cells |
| 9.00 |
Dr Matthew Boxer, NIH, USA
Pyruvate Kinase M2 Activators Induce Tetramerization and Reduce Tumor Size in Mouse Xenograft Models |
| 9.30 |
Dr Janeta Popovici-Muller, Agios Pharmaceuticals, USA
Discovery and Characterization of Mutant IDH Inhibitors for the Treatment of Cancer |
| 10.00 |
Dr Ken Bair, Forma Therapeutics, USA
Structure-based Identification of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors |
| 10.30 |
Dr Peter Dragovich, Genentech, USA
Design of Optimized Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors |
| 4.00 pm - 5.00 pm |
Back from the Slopes - Coffee and Cookie Break
|
| 5:00 pm – 8:00 pm |
Neglected Infectious Diseases and Parasitic Infections
|
| |
Chairman: Dr Richard Lee & Dr Kip Guy, St Judes Children's Research Hospital, USA
|
| 5.00 |
Dr Bryan Yeung , Novartis, Singapore
The Discovery, Optimisation, and Mode of Action of Spiroindolone Antimalarials |
| 5.45 |
Dr David Wilson, GlaxoSmithKline, UK
The Discovery and Optimization of Novel Anti-Malarial Agents Derived from Phenotypic Screening |
| 6.30 |
Professor Courtney Aldrich, University of Minnesota, USA
Rational Design of Antibiotics for Tuberculosis that Target Biotin Metabolism |
| 7.15 |
Professor Marvin Miller, University of Notre Dame, USA
Syntheses and Evaluation of New Anti-tuberculosis Agents Inspired by Studies of Mycobacterial Iron Assimilation |
| 10.00 pm - 11.00pm |
Hockey Practice |
| 7.00 am - 8.00 am |
Good Morning Buffet Breakfast
|
| 8:00 am – 11:00 am |
Academic Session - Indiana University
|
| |
Chairman: Professor Mike VanNieuwenhze, Indiana University, USA
|
| 8.00 |
Professor Nikki Pohl
Challenges in Glycan Synthesis |
| 8.30 |
Professor Silas Cook
The Quest for Affordable, Fully Synthetic Artemisinin |
| 9.00 |
Professor Richard DiMarchi
Chemical Biotechnology Applied to Endocrine Hormones |
| 9.30 |
Professor Erin Carlson
Chemoselective Enrichment for Natural Products Discovery |
| 10.00 |
Professor Charles Dann
Structural Insights into Targeted Drug Delivery via the Human Folate Receptors |
| 5:00 pm - 8:00 pm |
Frontiers in Synthesis
|
| |
Chairman: Professor Victor Snieckus, Queen's University, Canada
|
| 5.00 |
Professor Paul Chirik, Princeton University, USA
Base Metal Catalysis for Organic Synthesis |
| 5.45 |
Dr Scott Gilbertson, University of Houston, USA
Inhibitors of 5-HT2CR Protein:Protein Interactions for Stimulant Pharmacotherapy |
| 6.30 |
Dr Paul Richardson, Pfizer Worldwide R&D, USA
Facilitation of Scale-Up of Novel Oncology Candidates through Early Route Optimisation - Risk and Rewards |
| 7.15 |
Professor Janis Louie, University of Utah, USA
Advances in Ni- and Fe-Catalyzed Cycloaddition Chemistry |
| 10.00 pm |
Ice Hockey Game
|
| 7.00 am - 8.00 am |
Good Morning Buffet Breakfast
|
| 8:00 am – 11:00 am |
New Frontiers in Medicinal Chemistry
|
| |
Chairman: Dr Philippe Nantermet, Merck Research Laboratories, USA
|
| 8.00 |
Dr Matt Hayward, Pfizer, USA
Covalent Inhibitors in Drug Design |
| 8.35 |
Dr Steve Colletti, Merck, USA
Recent Advances in siRNA Delivery |
| 9.10 |
Dr Antonia Stepan, Pfizer, USA
The Impact of Oxetane and Bicyclo[1.1.1]pentane Motifs on Biopharmaceutical Properties |
| 9.45 |
Dr Colin Tice, Vitae Pharmaceuticals, USA
Drug Discovery and Optimization using Computer Generated Molecules with Predicted Potencies |
| 10.20 |
Dr Serge Boulet, Eli Lilly & Company, USA
Phenotypic Drug Discovery of Novel Anti-Angiogenics |
|
4:40 pm – 6:00 pm
|
Open Session
|
| |
Chairman: Dr Matt Hayward, Pfizer, USA
|
| 4.40 |
Dr Ed Olhava, Epizyme, USA
Studies Leading to the Clinical Candidate EPZ-5676, a DOT1L Inhibitor for the Treatment of MLL-rearranged Leukemia |
| 5.00 |
Dr Jamie Tuttle, Pfizer, USA
Discovery of a Series of Brain-Penetrant Kynurenine Aminotransferase II Inhibitors for the Treatment of Schizophrenia |
| 5.20 |
Dr Rolf Wagner, Abbott, USA
Discovery of HCV Polymerase Inhibitors ABT-333 and ABT-072: Components of an IFN-sparing Drug Regimen |
| 5.40 |
Dr Aaron Beeler, University of Boston, USA
"Development and Application of a Highly Selective Histone Deacetylase 8 Inhibitor" |
| 6:00 pm - 7:30 pm |
Poster Session
|
| |
Please submit an abstract for consideration to Dr Claire Francis. |
| 7.30pm - 10.00 pm |
Conference Banquet
|
| |
Keynote Speaker:
Dr. Peter Mueller
CSO & Executive VP, Global Research & Development, Vertex Pharmaceuticals, USA
|
| |
"Imagine: Pharma Be Fractal" |
| 7.00 am - 8.00 pm |
Good Morning Buffet Breakfast
|
| 8:00 am - 11:00 am |
Emerging Therapies for Hepatitis C
|
| |
Chairman: Dr John A. McCauley, Merck Research Laboratories, USA
|
| 8.00 |
Dr Omar Lopez, BMS, USA
Discovery of HCV NS5A Replication Complex Inhibitors |
| 8.45 |
Dr Will Watkins, Gilead, USA
Optimization of HCV NS5B Thumb Site II Inhibitors for Use in Interferon-Free Regimens
|
| 9.30 |
Dr Andrew Woodhead, Astex, USA
Discovery of a Novel Allosteric Mechanism for the Regulation of HCV NS3 Protein using Fragment Screening and Structure-Based Design |
| 10.15 |
Dr Deqiang Niu, Celgene, USA
The Discovery of a Potent and Selective Irreversible HCV Protease Inhibitor
|
| 4.00 pm - 5.00 pm |
Back from the Slopes - Coffee and Cookie Break
|
| 5:00 pm - 8:00 pm |
Treatment of Lipid Disorders: Metabolic Syndrome and Beyond
|
| |
Chairman: Dr Lance Pfeifer, Eli Lilly & Company, USA
|
| 5.00 |
Dr Jason Elliott , Novartis, USA
DGAT1 Inhibitors for Suppression of Postprandial Triglycerides |
| 5.45 |
Dr Amjad Ali, Merck Research Laboratories, USA
The Discovery and Development of Anacetrapib, a Potent and Orally Active CETP Inhibitor |
| 6.30 |
Dr Jon Seiders, BMS, USA
The Discovery and Optimization of a Novel Series of LPA Receptor Antagonists with Efficacy in Multiple Mouse Models of Fibrosis |
| 7.15 |
Dr Michael Vazquez, Pfizer, USA
Development of a Potent, Selective, and Orally Bioavailable mPGES-1 Inhibitor based on a Benzoxazole Template for the Treatment of Osteoarthritis Pain and Inflammation |
| 8.00pm |
Conference Closes |
Confirmed Attendees for the 2013 Conference
To view the attendees list you must be a registered user - or login here.
(Once you have logged in, remember to refresh this page).
If you would be interested in contacting any of the attendees prior to this conference, please contact the conference organiser.
We have made available abstracts in PDF form of most of the talks from this conference together with all Poster Abstracts from the Poster Session.
Conference Fees
| Conference Fee |
$775 |
| Exhibitor Registration |
$1,590 |
| (includes a 6ft table and one registrant) |
|
| Student or Postdoc |
$315 |
Payment is required at the time of registration.
Only registrations accompanied with payment will be accepted. Please register in advance.
Fees include course materials, welcome reception, keynote address and banquet and reception at poster session.
A full refund of registration fees, less a $15 administrative fee, will be available if requested in writing and received by December 24th 2011.
No refunds will be made after that date. A $30 fee also will be charged for returned checks.
(Please note that if you fail to cancel by the deadline and do not attend, you are still responsible for payment.)
MBCF reserves the right to cancel the 11th Winter Conference on Medicinal & Bioorganic Chemistry and return all fees in the event of insufficient registration. The liability of the MBCF and its partners is limited to the registration fee. The MBCF will not be responsible for any losses incurred by registrants, including but not limited to airplane cancellation charges or hotel deposits.
To register for this event please use this link.
From December to April our backyard is your winter fantasy. Enjoy the thrill of alpine skiing, snowboarding at Steamboat's only ski-in/ski-out resort.
The Sheraton Steamboat Resort is nestled at the base of one of the largest ski areas in North America, skiers will delight in world famous "champagne powder". Known as Ski Town USA, Steamboat has produced more Olympians than any other city in North America. Steamboat remains firmly linked to a Western tradition that sets it apart from every other ski resort in the world.
In the spring and summer months, whether your passion is championship golf, hiking, horseback riding, or just reveling in the beauty of the Colorado Mountains, the Sheraton Steamboat Resort can connect you to your adventure. The award-winning Rollingstone Ranch Golf Club, designed by Robert Trent Jones II, offers lessons, a driving range and 18 holes of spectacular golf.
A block of rooms have been reserved at the Sheraton Steamboat Resort. The room categories and prices are as follows:
Run of House Hotel Rooms $229 (Special Rate until October 31st 2012)
Run of House Hotel Rooms $259
Other Room Types Available:
One Bedroom Hotel Suite $469
Two Bedroom Hotel Suite $609
Studio King Village Inn Condominium $429
Deluxe One Bedroom Village Inn Condominium $469
Deluxe Two Bedroom Village Inn Condominium $609
Luxury Two Bedroom Village Inn Condominium $659
Premium Two Bedroom Village Inn Condominium $709
Two Bedroom Sheraton Villa $759
Three Bedroom Sheraton Villa $959
Three Bedroom Mountain View Sheraton Villa $999
These guest room rates will be offered by the Hotel 3 days prior and 3 days after the meeting dates.
All room rates are quoted exclusive of applicable state and local taxes, which are currently 11.4%.
An additional charge of $20 per room, per night will be added to each guest folio as a resort fee that will include local and 800 calls, in room high speed internet, shuttle service to downtown, self parking and ski storage.
Room rates are based on double occupancy. Additional adults will be charged $25 per night to occupy the room. Children 17 years and under stay free with an adult.
